Inhibikase Therapeutics (IKT) Invested Capital (2020 - 2025)
Historic Invested Capital for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to $72.9 million.
- Inhibikase Therapeutics' Invested Capital rose 1901590.35% to $72.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.9 million, marking a year-over-year increase of 1901590.35%. This contributed to the annual value of $95.0 million for FY2024, which is 73608.5% up from last year.
- As of Q3 2025, Inhibikase Therapeutics' Invested Capital stood at $72.9 million, which was up 1901590.35% from $80.1 million recorded in Q2 2025.
- Over the past 5 years, Inhibikase Therapeutics' Invested Capital peaked at $95.0 million during Q4 2024, and registered a low of -$385381.0 during Q3 2024.
- In the last 5 years, Inhibikase Therapeutics' Invested Capital had a median value of $25.4 million in 2023 and averaged $34.9 million.
- Per our database at Business Quant, Inhibikase Therapeutics' Invested Capital plummeted by 10254.09% in 2024 and then surged by 1901590.35% in 2025.
- Over the past 5 years, Inhibikase Therapeutics' Invested Capital (Quarter) stood at $38.4 million in 2021, then plummeted by 44.86% to $21.2 million in 2022, then crashed by 46.37% to $11.4 million in 2023, then surged by 736.08% to $95.0 million in 2024, then dropped by 23.25% to $72.9 million in 2025.
- Its Invested Capital stands at $72.9 million for Q3 2025, versus $80.1 million for Q2 2025 and $85.8 million for Q1 2025.